Subscribe to Life Science Success for cutting-edge insights, expert interviews, and a vibrant community. Your subscription fuels our mission and keeps you at the forefront of life sciences.
CEO of Previse DX
Dan Lunz is the CEO of Previse DX.
Established in 2017, Previse is a pioneering medical solutions company specializing in the prevention and early detection of cancer, focusing initially on esophageal cancer.
The Previse journey began as an exploration into a technology's viability for predicting esophageal cancer in patients with Barrett's esophagus, and it quickly revealed a genuine need among gastroenterologists.
Previse assembled a team renowned for their expertise in launching innovative diagnostic tests in the fields of early cancer detection, molecular diagnostics, and gastrointestinal-specific medical devices. The development of this technology was made possible through a grant from the National Institute of Health ("NIH") and decades of research conducted by Dr. Stephen Meltzer and his GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine.